巴雷特食管及早期肿瘤筛查工具验证与比较
一项前瞻性研究纳入1241例40-79岁首次接受胃镜或早期肿瘤内镜治疗的患者,比较6种临床风险工具对巴雷特食管(BE)及早期肿瘤的识别能力。结果显示各工具识别BE的AuROC为0.660-0.695,均优于单纯胃食管反流病(GERD)症状频率与持续时间(AuROC 0.579);HUNT、M-BERET和Kunzmann工具区分早期肿瘤与无BE的AuROC为0.763-0.796。
要点
- 临床风险工具识别BE的准确性均优于单纯GERD症状频率与持续时间。
- HUNT、M-BERET和Kunzmann工具对早期肿瘤的区分能力较好。
- 各工具预测风险与观察风险校准良好。
核心结论
- HUNT、M-BERET和Kunzmann工具识别BE的AuROC为0.665-0.695,区分早期肿瘤与无BE的AuROC为0.763-0.796。
- 这些工具在识别肿瘤性BE风险个体方面比GERD频率和持续时间更准确。
研究设计与样本
- 前瞻性研究,纳入1241例40-79岁首次接受食管胃十二指肠镜(EGD)或早期肿瘤性BE首次内镜治疗的患者,时间2015年4月至2018年6月。
- 计算6种已发表工具(Gerson、Locke、Thrift、M-BERET、HUNT、Kunzmann)的风险评分,并以内镜所见为参考标准比较判别能力。
- 另利用随机选取的50%首次EGD患者数据,分析GERD频率和持续时间的准确性。
主要发现
- 首次EGD的1152例患者中检出BE 81例(7.0%)。
- 单纯GERD症状识别BE的AuROC为0.579。
- 所有工具识别BE的AuROC范围为0.660-0.695,均高于GERD的0.579,且预测风险与观察风险校准良好。
- HUNT(AuROC 0.796)、M-BERET(0.773)和Kunzmann(0.763)工具在区分早期肿瘤(n=94)与无BE方面表现相当。
- 各工具区分BE伴早期肿瘤与无BE均优于单纯GERD频率和持续时间(AuROC 0.667;P < .01)。
临床怎么用
- 可考虑使用HUNT、M-BERET或Kunzmann工具筛选BE及早期肿瘤高风险个体,其准确性优于仅依赖GERD症状频率和持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Guidelines suggest endoscopic screening of individuals who are at increased risk for Barrett's esophagus (BE) and esophageal adenocarcinoma. Tools based on clinical factors are available for identifying patients at risk, but only some have been validated. We aimed to compare and validate available tools. METHODS: We performed a prospective study of 1241 patients, ages 40 to 79 years, presenting either for their first esophagogastroduodenoscopy (EGD) or their first endoscopic therapy of early neoplastic BE, from April 2015 through June 2018. We calculated risk scores for 6 previously published tools (the Gerson, Locke, Thrift, Michigan BE pREdiction Tool [M-BERET], Nord-Trøndelag Health Study [HUNT], and Kunzmann tools). We also investigated the accuracy of frequency and duration of gastroesophageal reflux disease (GERD), using data from a randomly selected 50% of patients undergoing their first EGD. We compared the ability of all these tools to discriminate patients with BE and early neoplasia from patients without BE, using findings from endoscopy as the reference standard. RESULTS: BE was detected in 81 of 1152 patients during their first EGD (7.0%). GERD symptoms alone identified patients with BE with an area under the receiver operating characteristic curve (AuROC) of 0.579. All of the tools were more accurate in identifying patients with BE than the frequency and duration of GERD (AuROC for GERD, 0.579 vs range for other tools, 0.660-0.695), and predicted risk correlated well with observed risk (calibration). The AUROCs of the HUNT tool (0.796), the M-BERET (0.773), and the Kunzmann tool (0.763) were comparable in discriminating between patients with early neoplasia (n = 94) vs no BE. Each tool was more accurate in discriminating BE with early neoplasia than GERD frequency and duration alone (AuROC, 0.667; P < .01). CONCLUSIONS: The HUNT, M-BERET, and Kunzmann tools identify patients with BE with AuROC values ranging from 0.665 to 0.695, and discriminate patients with early neoplasia from patients without BE with AuROC values ranging from 0.763 to 0.796. These tools are more accurate than frequency and duration of GERD in identifying individuals at risk for neoplastic BE.
引用
- Rubenstein JH, McConnell D, Waljee AK, et al. Validation and Comparison of Tools for Selecting Individuals to Screen for Barrett's Esophagus and Early Neoplasia. Gastroenterology. 2020. PMID: 32119928. doi:10.1053/j.gastro.2020.02.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。